Dr. Krishna Allamneni joined Turning Point Therapeutics in July 2019 as Vice President of Development Sciences.
Dr. Allamneni is responsible for leading the Repotrectinib project team, and managing development sciences function that encompasses toxicology, ADME/PK and bioanalytics. She has about 20 years of firsthand drug development and biotechnology industry experience, including 5 years at Roche/Genentech. She has been a key contributor to over a dozen IND/IMPD submissions and 5 NDA/MAA/sNDA approvals (Defitelio®, Vyxeos®, Xyrem®, Sunosi™). Most recently, she held the dual role of Executive Director global nonclinical R&D, and Asparaginase Franchise Early Development Team Leader at Jazz Pharmaceuticals. Previously, she directed preclinical development at NGM Biopharmaceuticals, Inc.
Dr. Allamneni serves on the Council for the American College of Toxicology, the Scientific Program Committee for the Society of Toxicology, and the editorial board for the International Journal of Toxicology. She holds a DVM, an MS/PhD in Pharmacology/Toxicology (University of California-Davis), a Pathology postdoctoral fellowship (Harvard Medical School), and is a Diplomate of the American Board of Toxicology (2002).